Chemomab Therapeutics Ltd.
CMMB evidence brief
What we can confirm
- BioSniper Score:
- 8.8 / 10
- Market Cap:
- $18.0M
What it means
What to watch
Prepared research question
What matters most for CMMB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CMMB
Chemomab Therapeutics Ltd. (CMMB) is a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting CCL24 for fibrotic and inflammatory diseases, with a lead program in primary sclerosing cholangitis (PSC).
Key risk: Single-product dependency
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$18.0M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Dec 31, 2025.
Chemomab Therapeutics Ltd. (CMMB) is a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting CCL24 for fibrotic and inflammatory diseases, with a lead program in primary sclerosing cholangitis (PSC).
- Clinical-stage biotech focused on fibrotic and inflammatory diseases, with lead candidate nebokitug (anti-CCL24) [sec · filed 2026-03-23].
- Cash & equivalents of $7.6M and shareholders' equity of $12.3M as of 2025-12-31 [sec].
- Lead program in PSC (orphan indications) with Phase 2 SPRING trial; early enrollment completion announced January 2024 [sec · filed 2025-04-04].
- Management team includes CEO/CSO with 16 years immunology experience and CMO with >25 years in clinical development [sec · filed 2025-04-04].
- No approved products; all programs require significant additional clinical development and funding [sec · filed 2026-03-23].
What works
- First-in-class monoclonal antibody targeting CCL24, a soluble protein with a pivotal role in fibrosis and inflammation [sec · filed 2026-03-23].
- Management team with deep experience: CEO/CSO 16 years in immunology, CMO >25 years in clinical development [sec · filed 2025-04-04].
- Phase 2 PSC SPRING trial completed enrollment early, suggesting operational efficiency [sec · filed 2025-04-04].
What to weigh
- Highly dependent on success of single lead candidate nebokitug; no approved products [sec · filed 2026-03-23].
- Substantial additional funding needed to complete development and commercialization; cash runway limited [sec · filed 2026-03-23].
- No history of successfully developing or commercializing a pharmaceutical product [sec · filed 2026-03-23].
From the filings
Quoted directly from source documents.
Company is clinical-stage and focused on fibrotic/inflammatory diseases
“We are a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet needs.”
SEC filings · March 23, 2026
Lead candidate nebokitug targets CCL24
“we have developed nebokitug, a monoclonal antibody designed to bind and block CCL24 activity.”
SEC filings · March 23, 2026
No approved products and need for substantial additional funding
“We currently have no products that are app”
SEC filings · March 23, 2026
Risks & what to watch (3)›
Key risks
- Single-product dependency — Business highly dependent on success of nebokitug; no other product candidates advanced [sec · filed 2026-03-23].
- Funding uncertainty — Will need substantial additional funding; if delayed or unable, may not complete development [sec · filed 2026-03-23].
- No commercialization track record — No history of successfully developing or commercializing a pharmaceutical product [sec · filed 2026-03-23].
What to watch
- Phase 2 PSC SPRING trial topline data readout (expected mid-2024 per Jan 2024 update) [sec · filed 2025-04-04].
- Ability to raise additional funding through equity, debt, or partnerships [sec · filed 2026-03-23].
- Progress of nebokitug toward registration trials and potential FDA approval [sec · filed 2026-03-23].
Sources: SEC filings · Generated October 12, 2026 · How we verify sources →
Run Chemomab Therapeutics Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Chemomab Therapeutics Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.12
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
2 buys · 0 sells (180d)
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
15
Total value held
$552K
| Holder | Shares | Value |
|---|---|---|
| adar1 capital management, llc | 80,000 | $126K |
| citadel advisors llc | 64,182 | $101K |
| kestra private wealth services, llc | 61,710 | $97K |
| ikarian capital, llc | 51,793 | $81K |
| xtx topco ltd | 18,629 | $29K |
| rhumbline advisers | 18,366 | $29K |
| smartharvest portfolios, llc | 14,566 | $23K |
| susquehanna international group, llp | 13,491 | $21K |
| bnp paribas financial markets | 8,425 | $13K |
| philadelphia investment partners, llc | 8,200 | $13K |
Showing top 10 of 15 institutional holders of Chemomab Therapeutics Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.7%
- Days to cover
- 1.3
- Shares short
- 47,374
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CMMB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Chemomab Therapeutics Ltd.?
Chemomab Therapeutics Ltd. (CMMB) is a clinical-stage biotechnology company developing nebokitug, a monoclonal antibody targeting CCL24 for fibrotic and inflammatory diseases, with a lead program in primary sclerosing cholangitis (PSC).
Who is the CEO of Chemomab Therapeutics Ltd.?
Dr. Adi Mor George Ph.D. is the chief executive officer of Chemomab Therapeutics Ltd. (CMMB).
Where is Chemomab Therapeutics Ltd. headquartered?
Chemomab Therapeutics Ltd. (CMMB) is headquartered in Tel Aviv-Yafo, Israel.
What therapeutic areas does Chemomab Therapeutics Ltd. focus on?
Chemomab Therapeutics Ltd. develops therapies across Immunology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.